SUDEP and mortality in developmental and epileptic encephalopathies: A meta‐analysis of randomized clinical trials and extension studies
Open Access
Abstract
Objective: Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic spasms syndrome (IESS). To address this gap, we conducted a Bayesian meta‐analysis of randomized controlled trials (RCTs) and corresponding long‐term open‐label extension (OLE) studies. Methods: All‐cause mortality and SUDEP incidence rates were estimated using hierarchical Bayesian models with moderately informative priors derived from the literature. A negative binomial likelihood was used for all‐cause mortality, whereas a Poisson likelihood was used for SUDEP. Subgroup analysis were conducted for DS, LGS, and IESS. Results: Thirty‐seven RCTs and 15 OLE studies were included, comprising 3757 patients with DEEs (2221 LGS, 998 DS, 369 IESS, and 169 other DEEs). Across pooled data, 37 deaths occurred, including 2 definite, 12 probable, and 1 possible SUDEP. In the overall DEE population, the Bayesian posterior median estimated mortality rate was 8.76 per 1000 person‐years (PY; 95% credible interval [CrI], 5.50–13.89), and SUDEP rate was 4.32 per 1000 PY (95% CrI, 2.66–6.64). In LGS, mortality was 7.05 per 1000 PY and SUDEP was 3.4 per 1000 PY. In DS, mortality was 8.0 per 1000 PY, with a SUDEP rate of 7.59 per 1000 PY. In IESS, mortality was 9.41 per 1000 PY and SUDEP was 2.79 per 1000 PY. Significance: SUDEP accounted for approximately half of deaths in the overall DEE population and in LGS, with a proportionally greater contribution in DS. Potential trial‐related underestimation should be considered when interpreting these findings, as features of trial‐based datasets could have contributed to lower observed mortality and SUDEP estimates. Prospective population‐based studies are needed to more accurately define the real‐world incidence of SUDEP in DEEs.Keywords
This publication has 54 references indexed in Scilit:
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trialEuropean Journal of Paediatric Neurology, 2024
- Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut SyndromeJAMA Neurology, 2022
- A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathiesEpilepsy Research, 2021
- Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorderAnnals of Clinical and Translational Neurology, 2021
- Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet SyndromeJAMA Neurology, 2020
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive RegimensJAMA Neurology, 2020
- Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303European Journal of Paediatric Neurology, 2019
- Mortality in Dravet syndromeEpilepsy Research, 2016
- Long-term safety and seizure outcome in Japanese patients with Lennox–Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trialEpilepsy Research, 2016
- Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: A randomized double-blind placebo-controlled trial in JapanEpilepsy Research, 2014